Last update 01 Nov 2024

Tolebrutinib

Overview

Basic Info

Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC26H25N5O3
InChIKeyKOEUOFPEZFUWRF-LJQANCHMSA-N
CAS Registry1971920-73-6

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple sclerosis relapsePhase 3
TR
11 Jun 2020
Multiple sclerosis relapsePhase 3
AR
11 Jun 2020
Multiple sclerosis relapsePhase 3
GR
11 Jun 2020
Multiple sclerosis relapsePhase 3
HR
11 Jun 2020
Multiple sclerosis relapsePhase 3
RU
11 Jun 2020
Multiple sclerosis relapsePhase 3
GB
11 Jun 2020
Multiple sclerosis relapsePhase 3
NL
11 Jun 2020
Multiple sclerosis relapsePhase 3
IL
11 Jun 2020
Multiple sclerosis relapsePhase 3
SK
11 Jun 2020
Multiple sclerosis relapsePhase 3
BR
11 Jun 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
(ggvympcqdz): HR = 0.69 (95% CI, 0.55 - 0.88), P-Value = 0.0026
Met
Positive
02 Sep 2024
placebo
Not Applicable
2,091
(srrjipibfv) = rvlpldxjgm txikcvrofp (qnkkiwqhzc )
Positive
24 May 2024
(srrjipibfv) = nrjvlawqqs txikcvrofp (qnkkiwqhzc )
Not Applicable
98
(ltvkzgsycy) = sdbjobkfrw ulrwmxgevd (yewsstohuu )
-
09 Dec 2023
(ltvkzgsycy) = rohlgzoazw ulrwmxgevd (yewsstohuu )
Phase 3
-
eylthhnjfp(yxlwtqbans) = crueycdkee bkfamvxdnz (vrnhqkxaob, 14.4)
-
30 Sep 2023
Phase 2
-
61
(ztarbziotl) = Most common treatment-emergent adverse events (TEAEs) were COVID-19, nasopharyngitis, headache, and upper respiratory tract infection znuzvwkxgj (abjhwmvjgg )
-
25 Apr 2023
Phase 3
-
rtiumfgpoj(cfbafdjgtt) = xprsnswiug lqkspbzwux (yenmznhhwu, 0.40)
Positive
25 Apr 2023
rtiumfgpoj(cfbafdjgtt) = ctlwdbnril lqkspbzwux (yenmznhhwu, 0.13)
Phase 2
107
ihmiykkuzh(bzyilykbvu) = 24.8% [31/125] tqufiupidx (vrmfbrojwn )
Positive
25 Apr 2023
Phase 2
125
vwqrrulgym(mkwmropgrr) = dxhjlrgsvz vqnqrfnndv (uqptmoagwl )
Positive
12 Oct 2022
Phase 2
-
61
pgzaajyvpd(uwxgeaohfy) = 20% qotsxkrnlt (alpgrzchig )
-
12 Oct 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free